Business Context and Reporting Period
This Form 8-K is filed by Aptevo Therapeutics Inc. (APVO) on July 1, 2025. The report addresses a specific regulatory event regarding the company's continued listing status on The Nasdaq Stock Market LLC.
Key Financial Metrics
- Capital Raised: Approximately $15.9 million in gross proceeds from additional equity capital during the quarter ended June 30, 2025.
- Stockholders' Equity: The company reports stockholders' equity of at least $2.5 million following the capital raise.
- Revenue, Profit, Cash Flow, Debt: The filing text does not provide clear values for revenue, net income, operating cash flow, or debt levels.
Material Changes
The primary material change is the restoration of compliance with Nasdaq Listing Rule 5550(b)(1). Previously, the company was non-compliant for the quarter ended March 31, 2025, due to stockholders' equity falling below the required $2.5 million minimum. The recent equity financing resolved this deficiency.
Outlook, Risks, and Management Commentary
- Regulatory Status: On July 1, 2025, the Nasdaq Listing Qualifications Staff confirmed the company has regained compliance with the minimum stockholders' equity requirement.
- Risk Mitigation: The risk of delisting due to insufficient equity has been temporarily mitigated by the June 2025 capital raise.
- Management Commentary: The filing confirms the company's belief that it now meets the listing standards based on the reported equity levels.
Investor Verification Checklist
- Verify the final audited stockholders' equity balance as of June 30, 2025, in the upcoming 10-Q or 10-K filing.
- Confirm the terms and dilution impact of the $15.9 million equity raise.
- Monitor future quarterly reports to ensure continued compliance with the $2.5 million equity threshold.
- Review the company's cash burn rate to assess the runway provided by the new capital.